OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
၄.၉၈ US$
arrow_upward
+၁.၁၂%(+၀.၀၅၅) 1D
အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
၅.၀၅ US$
High
၅.၀၇ US$
Low
၄.၉၈ US$
Mkt. cap
ဋေ ၁.၂၀ သိန်း
Avg. vol.
၆.၂၈ သောင်း
Volume
၂.၀၉ သောင်း
52-wk high
၅.၇၅ US$
52-wk low
၃.၈၂ US$
Beta
၀.၂၁
Shares outstanding
၁၄၉.၆၂ ဋေ
No. of employees
၄ ထောင်
Open
၅.၀၅ US$
High
၅.၀၇ US$
Low
၄.၉၈ US$
Mkt. cap
ဋေ ၁.၂၀ သိန်း
Avg. vol.
၆.၂၈ သောင်း
Volume
၂.၀၉ သောင်း
52-wk high
၅.၇၅ US$
52-wk low
၃.၈၂ US$
Beta
၀.၂၁
Shares outstanding
၁၄၉.၆၂ ဋေ
No. of employees
၄ ထောင်
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၂၈ မိနစ်
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
MarketBeat
·
ပြီးခဲ့သည့် ၅၄ မိနစ်
Turn Therapeutics (NASDAQ:TTRX) Cut to "Sell" at Wall Street Zen
MarketBeat
·
ပြီးခဲ့သည့် ၁ နာရီ
Amgen (NASDAQ:AMGN) Upgraded at Wall Street Zen
MarketWatch
·
ပြီးခဲ့သည့် ၁ ရက်
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees၄.၂၁ ထောင်
Founded၁၇၁၇
Headquartersအိုဆာကာမြို့, Osaka, ဂျပန်
Sector-
Websiteono-pharma.com